L'85% delle aziende farmaceutiche ha pagato sanzioni (per un totale di miliardi) e la maggior parte è stata impegnata in attività illegali per 4 o più anni.
The “Opioid Crisis” isn’t the only scandal perpetrated by Big Pharma, the Food and Drug Administration (FDA), and unethical doctors.
Thanks to Children’s Health Defense for alerting us to more Big Pharma corruption.
Big Pharma Paid Billions in Penalties for Illegal Practices, Study Shows
The peer-reviewed study found that 85% of the pharmaceutical
firms surveyed paid penalties and most engaged in illegal activities for
four or more years.
By Inside UNC Charlotte
A Belk College of Business researcher is examining the price large
pharmaceutical firms pay for their illegal practices. The study,
authored by Denis Arnold,
professor of management and Jule and Marguerite Surtman Distinguished
Professor of Business Ethics in the Belk College, found that over the
past 13 years, large pharmaceutical firms surveyed were penalized and
paid over $33 billion in penalties.
Published Tuesday, Nov. 17, in The Journal of the American Medical Association the peer-reviewed study found that 85% of the firms surveyed had paid penalties and most engaged in illegal activities for four or more years.
The most common penalties were pricing violations, off-label
marketing and kickbacks. Four firms had no penalties assessed during the
Arnold has authored or co-authored six papers on the pharmaceutical
industry, including two papers that document the industry’s failure to
adhere to their own self-regulatory guidelines regarding
Co-authors of the study are Oscar Jerome Stewart, Ph.D., San
Francisco State University, and Tammy Beck, University of
Nebraska-Lincoln (UNC). Stewart is an alumnus of UNC Charlotte’s
interdisciplinary Organizational Science doctoral program, and Beck previously served as a faculty member in the Belk College.
Arnold offers this insight from the study:
As someone who studies and teaches business ethics, are there any takeaways from your research?
The fact that four firms in the study had no incidences of misconduct
is an indication that it is possible to govern and lead large
pharmaceutical firms without engaging in illegal activity. Also, the
fact that when misconduct takes place, it does so over a period of many
years, indicates that it is intentional and not accidental, again
indicating poor governance and poor leadership.
As pharmaceutical firms gear up for mass vaccinations and
treatments for COVID-19, based on this research, is there anything we
should be looking out for?
Absolutely. Firms with high historical incidences of illegal activity
are more likely to engage in the fraudulent representation of research
data, the suppression of negative side-effects, and the false marketing
of their products. It is very much related to COVID-19
research in that a firm with a history of misconduct would have a
higher probability of lying about the efficacy of their vaccines or
Are penalties just part of doing business?
It is only part of doing business if one believes that illegal
activity is a legitimate business strategy. Otherwise, it is an
indication of poor governance and leadership. Further, research I have
done with Belk College colleagues Ted Amato (Economics) and Dean Jennifer Troyer
(Economics) provides evidence that links illegal activity with reduced
drug innovation. In other words, cheating is a substitute for
The billions of dollars in penalties — nearly $10 billion in the case
of GlaxoSmithKlein — could instead have been spent on research and
What can government regulators learn from your research?
Aggressive oversight and enforcement are vital to ensure that
pharmaceuticals are safely utilized and that pricing is consistent with
federal regulations. In particular, to deter such behavior, it will be
important to act on 2015 guidance from the Department of Justice, which
requires that executives, and not just shareholders, be held liable for
corporate misconduct. In addition, providing consistent and strong
incentives for whistle-blowers is essential. Finally, there is ample
room for additional regulation to better protect Americans from false or
misleading information regarding drug efficacy and overpricing.
Since prescription drugs are critical to the health of citizens, should big pharmaceuticals be held to a higher standard?
All large pharmaceutical companies pledge to improve human welfare.
Yet, the majority use marketing and pricing strategies that harm patient
welfare to improve their bottom lines. Because of this hypocrisy, the
pharmaceutical industry consistently ranks at the bottom among Gallup’s
U.S. industry reputation rankings.
Published with permission from Inside UNC Charlotte.
The views and opinions expressed in this article are those of the
authors and do not necessarily reflect the views of Children’s Health
Inside UNC Charlotte
Inside UNC Charlotte is produced and maintained by the Office of
University Communications; campus communicators, who include individuals